Navigation Links
ChemImage and Next Breath Structure Partnership to Validate Bioequivalence Testing for Nasal Spray Suspensions
Date:4/1/2009

Testing Will Help Advance Technology to Find a Faster, More Accurate and Repeatable Method for Drug-Particle Sizing

PITTSBURGH, April 1 /PRNewswire/ -- ChemImage, (www.chemimage.com) today announces a strategic research partnership with Next Breath, LLC (www.nextbreath.net), a leading Contract Research Organization (CRO) to further validate ChemImage's Raman Chemical Imaging for bioequivalence applications for nasal spray suspensions.

Baltimore, MD-based Next Breath focuses on conducting in vitro bioequivalence testing for nasal sprays and chemistry, manufacturing and controls (CMC) testing for inhalation and nasal spray products, and is particularly interested in advancing the technology to find a faster and reproducible method for drug-particle sizing relative to bioequivalence studies for nasal spray suspensions.

"We are proud to partner with Next Breath because our goal at ChemImage is to validate our bioequivalence testing methodology," said Ryan Priore, Senior Scientist, ChemImage. "Pharmaceutical companies, particularly generic drug manufacturers focused on nasal spray suspensions, are looking to improve their time-to-market through the use of better imaging technology. The potential payoff is a faster, more accurate and safe way to bring the drug to market."

ChemImage, one of the world's leading chemical and biological imaging technology solutions companies, will be partnering with Next Breath to compare optical microscopy to Raman Chemical Imaging, specifically ChemImage's FALCON II(TM) Wide-Field Raman Chemical Imaging System.

The FALCON II enables drug manufacturers to perform chemical imaging of particles in droplets to distinguish the identity, particle size distribution of drug and other substances, aggregation, and the correlation about the location of the material in the formulation -- something drug makers have been unable to achieve in the past with standard optical microscopy as part of bioequivalence testing.

"Clearly, ChemImage has the potential to advance the ability of drug manufacturers to more accurately assess their risk when going into clinical trials by providing them with a more objective active ingredient particle size analysis between the Test and Reference Drug Product. Our work with ChemImage will help validate their Raman Chemical Imaging technology and services to perform in vitro drug particle size distribution measurements," said Julie Suman, President, Next Breath, LLC.

ChemImage's FALCON II is currently available for sale across international markets. ChemImage also offers imaging lab services for companies interested in expediting bioequivalence testing. The company expects the additional validation testing to be conducted in 2009 and 2010.

ChemImage and Next Breath will be attending the Nasal Drug Delivery Conference on April 1st - 2nd, 2009 in London.

About Next Breath

Next Breath is a contract services provider for pharmaceutical, biotech and medical device companies that bring new inhalation and nasal products to market. The company provides an array of in-vitro services, from pre-clinical formulation development to analytical testing in support of submissions to regulatory agencies. Its mission is to serve as an effective liaison between innovators of promising drug molecules and inventors of pulmonary and nasal drug delivery devices.

About ChemImage

ChemImage Corporation, headquartered in Pittsburgh, is a world leader in Chemical Imaging technologies; provides instrumentation, software, lab services and expert consulting to government, industrial and academic organizations. ChemImage offers these products and services for a range of applications including defense, security, pharmaceuticals, forensics and biomedical diagnostic research. Its state-of-the-art Chemical Imaging technology can help to reveal critical chemical and biological information about processes, products and services.


'/>"/>
SOURCE ChemImage
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
2. Two nanostructures are better than one
3. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
4. NIST team develops novel method for nanostructured polymer thin films
5. Smart insulin nanostructures pass feasibility test, UT study reports
6. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
7. Researchers outline structure of largest nonvirus particle ever crystallized
8. CME LLC Restructures, Announces Its New Executive Management Team
9. Ames Laboratory researchers solve fuel-cell membrane structure conundrum
10. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
11. DRI Capital Launches Structured Finance Fund
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... New York (PRWEB) , ... February 11, 2016 ... ... analytical instruments for more than 150 years, continues today to pursue the highest ... its line of analytical instruments: the AR9 Refractometer and the AR5 Refractometer. ...
(Date:2/10/2016)... , February 10, 2016 Early-career researchers ... Peru , Uganda and ... work in health and nutrition   Indonesia , ... Uganda and Yemen are being honored ... epidemiology. They are also celebrated for mentoring young women scientists who are ...
(Date:2/10/2016)... Tarrytown, New York, and New York, New York (PRWEB) , ... ... ... Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) today announced that ... discover and develop new vaccines and immunotherapies for infectious diseases and cancer. ...
(Date:2/10/2016)... ... 2016 , ... Benchmark Research, a fully-integrated network of ... principal investigators (PI) to the roles of Chief Medical Officer, Clinical Research and ... Chu, a Benchmark Research PI in the Austin office, will assume the role ...
Breaking Biology Technology:
(Date:2/9/2016)... Vigilant Solutions announces today that an agency used its Vigilant ... in a difficult homicide case. The agency then used Vigilant,s ... vehicle. Due to the ongoing investigation, the agency name and ... agency,s request. --> --> ... deceased at an intersection here in the City. He had ...
(Date:2/3/2016)... 2016 --> ... "Automated Fingerprint Identification System Market by Component (Hardware and ... & Finance, Government, Healthcare, and Transportation) and Geography - ... is expected to be worth USD 8.49 Billion by ... and 2020. The transformation and technology evolution from the ...
(Date:2/2/2016)... 2016 Checkpoint Inhibitors for Cancer – ... Are you interested in the future of cancer ... inhibitors. Visiongain,s report gives those predictions to 2026 ... level. Avoid falling behind in data or ... revenues those emerging cancer therapies can achieve. There ...
Breaking Biology News(10 mins):